Middle East and Africa Botulinum Toxin Market Overview and Growth by 2030

The Middle East and Africa botulinum toxin market size is expected to reach US$ 453.55 million by 2030 from US$ 172.57 million in 2022. The market is estimated to record a CAGR of 12.8% from 2022 to 2030.

Market Insights and Analyst View:

Botox injections block chemical signals from nerves that cause muscle contraction. The injections relax the facial muscles that cause frown lines and other facial wrinkles. Botox is a drug developed from a toxin produced by the bacterium Clostridium botulinum. There are various types of botulinum toxin, with types A and B being commonly used for medical and cosmetic purposes.

Botulinum toxin is used for the treatment of various medical conditions, including chronic migraines, muscle spasms, and certain neurological disorders. It is also widely known for its cosmetic applications, particularly in the form of Botox injections, to reduce the appearance of facial wrinkles and fine lines. In medical and cosmetic settings, botulinum toxin is injected directly into specific muscles. The toxin blocks nerve signals in the injected muscles, causing temporary muscle paralysis. The effects of botulinum toxin are temporary, typically lasting for a few months. Repeat injections are often necessary to maintain the desired results.

While botulinum toxin is generally considered safe when administered by medical professionals in appropriate doses, there can be side effects and risks. Common side effects include temporary bruising and muscle weakness. It is crucial for individuals considering botulinum toxin treatments to consult with qualified healthcare professionals to assess suitability and discuss potential risks and benefits. Additionally, regulations regarding the use of botulinum toxin may vary by country and region.

The Middle East & Africa botulinum toxin market is growing rapidly due to a number of factors, such as increasing disposable incomes in the Middle East, rising awareness regarding the benefits of botulinum toxin, growing prevalence of neurological disorders, and increasing applications of botulinum toxin in the treatment of various diseases. The market is also expected to benefit from the development of new and innovative botulinum toxin products and applications. However, side effects associated with the botulinum toxin hamper the Middle East and Africa botulinum toxin market growth.

Growth Drivers and Challenges:

Rising Awareness Regarding Benefits of Botulinum Toxin Drives Middle East and Africa Botulinum Toxin Market Growth

People in the Middle East are willing to spend money on aesthetic procedures due to a rise in disposable incomes. Botulinum toxin injections are a popular aesthetic procedure as they are relatively quick, easy, and effective. People in the Middle East are becoming more aware of the benefits of botulinum toxin injections, both for aesthetic and therapeutic purposes. Botulinum toxin injections can be used to treat wrinkles, frown lines, and crow's feet. Botulinum toxin is an effective and safe treatment for various neurological disorders, including spasticity, dystonia, and migraine headaches. The rising prevalence of neurological disorders in the Middle East drives demand for botulinum toxin injections. Botulinum toxin injections are increasingly being used to treat hyperhidrosis or excessive sweating. Hyperhidrosis can be a debilitating condition that can affect a person's social and professional life. Botulinum toxin injections can provide effective relief from hyperhidrosis symptoms. Minimally invasive procedures are becoming increasingly popular, as they are associated with less pain, scarring, and recovery time than traditional surgical procedures. Botulinum toxin injections are minimally invasive procedures that can be performed in a doctor's office. Owing to the factors mentioned above, the Middle East and Africa botulinum toxin market is expected to grow in the coming years.

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Middle East and Africa Botulinum Toxin Market: Strategic Insights

Middle East and Africa Botulinum Toxin Market

• Market Size 2022
  US$ 172.57 Million
• Market Size 2030
  US$ 453.55 Million

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Product

• Botox
• Dysport
• Xeomin

Application

• Medical and Aesthetic

and End User

• Specialty and Dermatology Clinics
• Hospitals and Clinics

Segmentation and Scope:

The “Middle East & Africa Botulinum Toxin Market” is segmented on the basis of product, application, end-user, and Country. 

Based on product, the Middle East and Africa botulinum toxin market is segmented into Botox, Dysport, Xeomin, and others. The Botox segment held the largest market share in 2022 and is expected to retain its dominance during the forecast period. By application, the market is bifurcated into medical and aesthetic. The medical segment held a larger market share in 2022. However, the aesthetic segment is anticipated to register a significant CAGR during the forecast period. The botulinum toxin market, by end-user, is segmented into hospitals and clinics, specialty and dermatology clinics, and others. The specialty and dermatology clinics segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR in the market during the forecast period.

Segmental Analysis:

The medical segment led the Middle East and Africa botulinum toxin market in 2022 and is expected to retain its dominance during the forecast period. Botulinum toxin is widely used to treat medical conditions such as chronic migraine, adult spasticity, pediatric spasticity, and others. For migraine conditions, onabotulinumtoxin A is a prescription medication injected into the muscle with clinical effects such as preventing headaches among adults with chronic migraine.

Botulinum toxin is one of the most versatile agents in the aesthetic field. It has been used for numerous applications, such as the treatment of glabellar and forehead lines, eyebrow repositioning, and periorbital wrinkles.

Regional Analysis:

Based on country, the Middle East and Africa botulinum toxin market is segmented into Saudi Arabia, the UAE, South Africa, Lebanon, Oman, Jordan, Qatar, Kuwait, Bahrain, and the Rest of the Middle East & Africa. Saudi Arabia held the largest market share, followed by the UAE.

Saudi Arabia is one of the largest markets in the Middle East and Africa regarding population and economy. In recent years, there has been an increase in the number of cosmetic procedures, either surgical or non-surgical. According to a study conducted by the International Society of Aesthetic Plastic Surgeons, Saudi Arabia ranks 22nd among the top 25 countries with the highest rates of cosmetic procedures in the world. Acceptance of less invasive procedures such as botulinum toxin, dermal fillers, laser, and chemical peels increased among middle-aged women to have a natural look without significant downtime.

Furthermore, increasing product approvals for treating glabellar lines is expected to impact the Middle East and Africa Botulinum toxin market positively. In October 2022, Daewoong Pharmaceutical announced that it had obtained product approval from the Saudi Arabian and Ukrainian governments for Nabota, a botulinum toxin (BTX) product.

Therefore, the factors mentioned above fuel the growth of the Middle East and Africa Botulinum toxin market in Saudi Arabia.

Competitive Landscape and Key Companies:

Organic and inorganic growth strategies have characterized developments in the Middle East and Africa botulinum toxin market. Various companies focus on organic growth strategies such as launches, expansion, enhancement, and relocation. Inorganic growth strategies witnessed in the market were mergers & acquisitions, partnerships, and collaborations. These activities have paved the way for the expansion of businesses and the customer base of Middle Eastern and African botulinum toxin market players.

• In February 2022, Merz Therapeutics announced that it will expand its strategic partnership with Vensica Therapeutics as the Merz Group invests up to US$3 million in the Israeli start-up. This investment follows the strategic license and collaboration agreement signed in 2021 to utilize Merz’s botulinum neurotoxin A (XEOMIN) for the innovative ultrasound-assisted delivery catheter of Vensica. Merz is thus executing its contractually agreed option to participate in Vensica’s Series C financing round and invest further in the start-up. 
• In August 2021, Merz Therapeutics and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced that they have entered into a strategic license and collaboration agreement to deliver botulinum neurotoxin A (XEOMIN) to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter. By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder, interstitial cystitis, and other urology indications.

Company Profiles

• Merz Pharma GmbH & Co KGaA
• AbbVie Inc
• Revance Therapeutics Inc
• Ipsen SA
• Medytox Inc
• Evolus Inc
• Hugel Inc
• Lanzhou Institute of Biological Products Co Ltd
• Gufic
• Metabiologics, Inc.